A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
A phase 1/2 trial of Lenalidomide, Rituximab in follicular lymphoma, run by Enterome, now recruiting.
Overview
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT04669171 by Enterome, with 80 participants planned, started 2021-07-05 and due to reach its primary completion in 2029-05-30. Interventions recorded: EO2463, lenalidomide, rituximab. Conditions listed: Follicular Lymphoma, Marginal Zone Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- CompanyBiogen
Shares Rituximab, Follicular lymphoma.
- TrialA Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialA Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialMIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Shares Lenalidomide, Follicular lymphoma.